EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Transthyretin Amyloid Cardiomyopathy in Aortic Stenosis Patients Scheduled for Transcatheter Aortic Valve Implantation

Margrethe Flesvig Holt, August Flø, Esra Kaya, Sophie Foss Kløve, Hege Martinsen, Kristine Amlie, Petter Storsten, Thomas Misje Mathiisen, Kristoffer Russell, Christian Hesbø Eek, Helge Skulstad, Melinda Raki und 4 weitere

ESC Heart Failure · 01.08.2025 · 12 (4) · 2467-2476

DOI: 10.1002/ehf2.15258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 11.03.2025. Verfasst von Margrethe Flesvig Holt und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Cardiomyopathies, Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bergesen Foundation, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The prevalences of aortic stenosis (AS) and transthyretin amyloid cardiomyopathy (ATTR-CM) increase with age. Identification of occult ATTR-CM in patients with AS can help explain out-of-proportion myocardial dysfunction, aid in prognostication and prompt initiation of disease-modifying treatment. Studies have suggested that many patients referred for transcatheter aortic valve implantation (TAVI) have concomitant ATTR-CM, but some have included unverified ATTR-CM in patients with ambiguous scintigrams. We aimed to assess the co-occurrence of ATTR-CM in patients scheduled for TAVI.

Methods

In patients accepted for TAVI for severe AS, we used bone scintigraphy to screen for ATTR-CM. We defined ATTR-CM as a cardiac tracer uptake ≥ Perugini Grade 2 in the absence of abnormal monoclonal protein or abnormal free light chain ratio. We offered bioptic verification to patients with Grade 1 or ambiguous DPD uptake.

Results

We included 171 consecutive patients aged 79 ± 7 years, 57% were male. Six patients (3.5%) had cardiac bone tracer uptake ≥ Perugini Grade 2 and no abnormal monoclonal protein/free light chains. Endomyocardial biopsies confirmed the diagnosis in two additional patients (1.2%), whereas five patients with low-grade uptake did not have ATTR-CM. In total, 8/171 patients (4.7%) were diagnosed with concomitant AS and ATTR-CM. Most of the patients with concomitant ATTR-CM had low-flow low-gradient (LFLG) AS, and 25% had a history of carpal tunnel syndrome.

Conclusions

We found concomitant AS and ATTR-CM in 5% of our TAVI patients. Carpal tunnel syndrome and LFLG AS suggest concomitant ATTR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisTranscatheter Aortic Valve ReplacementCardiomyopathiesAmyloid Neuropathies, FamilialHumansMaleFemaleAgedAged, 80 and overRetrospective StudiesFollow-Up Studies

Stichwörter der Autor:innen

ATTR‐CMTAVIaortic stenosisbone scintigraphycardiac amyloidosisendomyocardial biopsy

Autor:innen und Institutionen

  • Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • KG Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.
  • Department of Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
  • ProCardio Center for Innovation, Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
  • Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Förderung

  • Bergesen Foundation
  • Pfizer

Zitieren

APA

Holt, M. F., Flø, A., Kaya, E., Kløve, S. F., Martinsen, H., Amlie, K., Storsten, P., Mathiisen, T. M., Russell, K., Eek, C. H., Skulstad, H., Raki, M., Gullestad, L., Hodt, A., Gude, E., & Broch, K. (2025). Transthyretin Amyloid Cardiomyopathy in Aortic Stenosis Patients Scheduled for Transcatheter Aortic Valve Implantation. ESC Heart Failure, 12(4), 2467-2476. https://doi.org/10.1002/ehf2.15258

Vancouver

Holt MF, Flø A, Kaya E, Kløve SF, Martinsen H, Amlie K, et al. Transthyretin Amyloid Cardiomyopathy in Aortic Stenosis Patients Scheduled for Transcatheter Aortic Valve Implantation. ESC Heart Failure. 2025;12(4):2467-2476. doi:10.1002/ehf2.15258

BibTeX
@article{Holt2025,
  author = {Holt, Margrethe Flesvig and Flø, August and Kaya, Esra and Kløve, Sophie Foss and Martinsen, Hege and Amlie, Kristine and Storsten, Petter and Mathiisen, Thomas Misje and Russell, Kristoffer and Eek, Christian Hesbø and Skulstad, Helge and Raki, Melinda and Gullestad, Lars and Hodt, Anders and Gude, Einar and Broch, Kaspar},
  title = {Transthyretin Amyloid Cardiomyopathy in Aortic Stenosis Patients Scheduled for Transcatheter Aortic Valve Implantation},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {4},
  pages = {2467--2476},
  doi = {10.1002/ehf2.15258}
}
Kostenlos starten →